Sodium-Glucose Cotransporter-2 Inhibitors in Liver Cirrhosis: A Systematic Review of Their Role in Ascites Management, Slowing Disease Progression, and Safety
International Journal of Molecular Sciences · 16.05.2025 · 26 (10) · 4781
DOI: 10.3390/ijms26104781 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 16.05.2025. Verfasst von Sudheer Dhoop und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, The University of Toledo, 3333 Glendale Ave., Toledo, OH 43614, USA. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Liver Cirrhosis, Ascites. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Sodium-glucose cotransporter-2 inhibitors (SGLT2Is) are widely used for type 2 diabetes mellitus (T2DM), conferring cardiovascular and renal benefits with evidence supporting their role in metabolic-associated steatotic liver disease (MASLD), the fastest rising etiology for liver cirrhosis. Our study collects and synthesizes all available data on SGLT2I use in liver cirrhosis to summarize their potential benefits and risks. We systematically reviewed the literature on SGLT2I use in adults with cirrhosis, focusing on 6 outcome domains, including ascites reduction, disease progression, hemodynamics, acute kidney injury (AKI), electrolyte abnormalities, and infection risk. We identified 16 studies: compensated (n = 5), decompensated (n = 3), and refractory ascites (n = 8). All studies of decompensated cirrhosis (n = 11) reported ascites reduction. Most studies (7 of 9) indicated SGLT2Is slowed disease progression by reducing clinical decompensation (n = 4) or improving laboratory markers (n = 3). A minority of studies revealed safety concerns with 2 of 9 studies showing evidence of hemodynamic instability and acute kidney injury (AKI), 2 out of 13 for electrolyte abnormalities, and 2 out of 5 for infection risk. Current evidence strongly supports SGLT2Is for refractory ascites management and suggests potential benefits in slowing progression across cirrhosis severities. Longer-term prospective trials in patients with non-refractory decompensated cirrhosis and real-world safety data are essential to clarify and potentially expand the role of SGLT2Is in cirrhosis management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, The University of Toledo, 3333 Glendale Ave., Toledo, OH 43614, USA.
- Division of Gastroenterology and Hepatology, The University of Toledo, 3333 Glendale Ave., Toledo, OH 43614, USA.
- College of Medicine and Life Sciences, The University of Toledo, 3000 Arlington Ave., Toledo, OH 43614, USA.
- University Library, The University of Toledo, 2801 W. Bancroft St., Toledo, OH 43606, USA.
- Department of Biological Sciences, Wayne State University, 4841 Cass Ave., Detroit, MI 48201, USA.
ORCID-Profile: Sudheer Dhoop, Wade-Lee Smith, Bisher Sawaf, Priya Vadehra
Zitieren
APA
Dhoop, S., Ghazaleh, S., Roberts, L., Shehada, M., Patel, M., Smith, W. L., Rabeeah, S., Sawaf, B., Vadehra, P., Hart, B., & Hassan, M. (2025). Sodium-Glucose Cotransporter-2 Inhibitors in Liver Cirrhosis: A Systematic Review of Their Role in Ascites Management, Slowing Disease Progression, and Safety. International Journal of Molecular Sciences, 26(10), 4781. https://doi.org/10.3390/ijms26104781
Vancouver
Dhoop S, Ghazaleh S, Roberts L, Shehada M, Patel M, Smith WL, et al. Sodium-Glucose Cotransporter-2 Inhibitors in Liver Cirrhosis: A Systematic Review of Their Role in Ascites Management, Slowing Disease Progression, and Safety. International Journal of Molecular Sciences. 2025;26(10):4781. doi:10.3390/ijms26104781
BibTeX
@article{Dhoop2025,
author = {Dhoop, Sudheer and Ghazaleh, Sami and Roberts, Luke and Shehada, Mohammed and Patel, Manthanbhai and Smith, Wade-Lee and Rabeeah, Sana and Sawaf, Bisher and Vadehra, Priya and Hart, Benjamin and Hassan, Mona},
title = {Sodium-Glucose Cotransporter-2 Inhibitors in Liver Cirrhosis: A Systematic Review of Their Role in Ascites Management, Slowing Disease Progression, and Safety},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {10},
pages = {4781},
doi = {10.3390/ijms26104781}
}
EUVIMED